following a full submission assessed under the end of life and orphan medicine process:
atezolizumab (Tecentriq®) is accepted for use within NHSScotland.
Indication under review: Atezolizumab, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
In one randomised, double-blind phase III study, the combination of atezolizumab with carboplatin and etoposide was associated with modest significant improvements in progression free survival and overall survival compared with chemotherapy alone in adult patients with untreated ES-SCLC.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- atezolizumab (Tecentriq)
- SMC ID:
In combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer.
- Pharmaceutical company
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 09 November 2020